Humanised anti-interleukin-18 antibody
The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
1. A humanised anti-interleukin-18 antibody comprising a heavy chain and light chain comprising the following complementarity determining regions (CDRs):
CDRH1: SEQ ID NO:1;
CDRH2: SEQ ID NO:2;
CDRH3: SEQ ID NO:3;
CDRL1: SEQ ID NO:4;
CDRL2: SEQ ID NO:5; and
CDRL3: SEQ ID NO:6,
wherein said antibody comprises a heavy chain selected from the group consisting of: SEQ ID NO: 9, SEQ ID NO: 17, and SEQ ID NO: 21; and a light chain selected from the group consisting of: SEQ ID NO: 13 and SEQ ID NO: 29.
2. The humanised anti-interleukin-18 antibody as claimed in claim 1 , said antibody comprising a heavy chain comprising SEQ ID NO:9 and a light chain comprising SEQ ID NO:13, or a heavy chain comprising SEQ ID NO:9 and a light chain comprising SEQ ID NO:29.
3. The humanised anti-interleukin-18 antibody as claimed in claim 1 , said antibody comprising a heavy chain comprising SEQ ID NO:17 and a light chain comprising SEQ ID NO:13, or a heavy chain comprising SEQ ID NO:17 and a light chain comprising SEQ ID NO:29.
4. The humanised anti-interleukin-18 antibody as claimed in claim 1 , said antibody comprising a heavy chain comprising SEQ ID NO:21 and a light chain comprising SEQ ID NO:13, or a heavy chain comprising SEQ ID NO:21 and a light chain comprising SEQ ID NO:29.
5. A humanised anti-interleukin-18 antibody comprising a heavy chain comprising SEQ ID NO:9 and a light chain comprising SEQ ID NO:13.
6. A humanised anti-interleukin-18 antibody, wherein said antibody comprises a heavy chain selected from the group consisting of: SEQ ID NO:9, SEQ ID NO:17, and SEQ ID NO:21.
7. A humanised anti-interleukin-18 antibody, wherein said antibody comprises a light chain selected from the group consisting of: SEQ ID NO:13 and SEQ ID NO:29.